Drugs / [11C]MK-6884
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02621606 | Jan 2016 → Dec 2017 | Alzheimer disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [11C]MK-6884 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02621606 ↗ |
| Modality | Diagnostic / imaging agent | “positron emission tomography (PET) imaging agent” NCT02621606 ↗ |
| Route | Intravenous | “single intravenous (IV) dose” NCT02621606 ↗ |